Welcome to
Sanofi in Canada
Toggle navigation
About Us
Science & Innovation
Products and Resources
Patient Support
Our Responsibility
Careers
Media
Toggle navigation
News Releases
Subscribe
Media Contacts
Social Media
News
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Subscribe
Year
All Years
2024
2023
2022
2021
2020
2019
2018
2017
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Photos
Video
Audio
Documents
Events
Standard
Sep 12, 2024
DUPIXENT® (dupilumab injection) approved in Canada for the treatment of children aged 1 year and older with eosinophilic esophagitis (EoE)
Jul 26, 2024
Fluzone® High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza
Jul 25, 2024
Ontario Ministry of Health Announces a Universal Public Program with Beyfortus® this RSV Season
Jun 18, 2024
Sanofi Canada celebrates winners of the 2024 Biogenius Competition and awards fourth annual Biogenius Grants
Photos
1
May 31, 2024
Quebec Ministry of Health Announces Universal Public Program with Beyfortus® this Upcoming RSV Season
May 30, 2024
SANOFI OPENS NEW ADVANCED VACCINES FACILITY, STRENGTHENING ITS COMMITMENT TO BIOMANUFACTURING IN CANADA
Photos
1
May 21, 2024
The National Advisory Committee on Immunization recommends BEYFORTUS® to protect all infants against RSV
Apr 18, 2024
Quebec's INESSS recommends BEYFORTUS® for the prevention of RSV for all infants 8 months of age and younger(1)
Apr 16, 2024
Sanofi Canada invests $180M CAD to build and update infrastructure to minimize environmental footprint at its Toronto Campus by 50%
Photos
1
Mar 19, 2024
2024 Sanofi Biogenius Canada Grants open for applications
Photos
1
Feb 20, 2024
JDRF Canada and Sanofi Canada partner to raise awareness about autoimmune type 1 diabetes and the critical role of screening in its early detection
Photos
1
Jan 30, 2024
Sanofi Canada is celebrating 110 years of innovative health solutions for Canadians
Jul 25, 2023
Sanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact
Jul 17, 2023
Dupixent® (dupilumab injection) receives marketing authorization for prurigo nodularis
Jul 6, 2023
Sanofi Canada awards third annual Sanofi Biogenius Canada Grants to enhance STEM learning for students
Jun 13, 2023
Sanofi Canada Celebrates Winners of the 2023 Sanofi Biogenius Canada Competition
Jun 12, 2023
Icy Hot® Partners with KidSport Canada to Help Kids Get in the Game
May 4, 2023
DUPIXENT® (dupilumab injection) is now approved in Canada for the treatment of adult and adolescent patients (12+) with Eosinophilic Esophagitis
May 1, 2023
Libtayo® (cemiplimab) in Combination with Chemotherapy now approved in Canada for the First-line Treatment of Advanced Non-small Cell Lung Cancer
May 1, 2023
Sanofi Canada and Diabetes Care Community announce a collaboration to support the emotional well-being journey of Canadians living with diabetes
Apr 24, 2023
Health Canada approves BEYFORTUS™ (nirsevimab) for the prevention of RSV disease in infants
Apr 20, 2023
DUPIXENT® (dupilumab injection) now approved in Canada for children as young as six months old with severe atopic dermatitis
Mar 21, 2023
Notice of Compliance issued regarding Rezurock(TM) (belumosudil tablets)
Mar 8, 2023
Sanofi Canada Maintains Gender Parity Certification, Achieving Platinum Level
Photos
1
Jan 18, 2023
Health Canada accepts nirsevimab regulatory submission for infant RSV
Show
5
10
25
50
100
per page
«
1
2
3
4
5
»
